Citations (71)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Yasemin Taş Torun, Yasemen Işik Taner, Esra Güney & Elvan İseri. (2022) Osmotic Release Oral System-Methylphenidate Hydrochloride (OROS-MPH) versus atomoxetine on executive function improvement and clinical effectiveness in ADHD: A randomized controlled trial. Applied Neuropsychology: Child 11:4, pages 567-578.
Read now
Read now
Qiang Liu, Hong Zhang, Qingqing Fang & Lili Qin. (2017) Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: Meta-analysis based on head-to-head trials. Journal of Clinical and Experimental Neuropsychology 39:9, pages 854-865.
Read now
Read now
Lise Aagaard & Ebba Holme Hansen. (2011) The occurrence of adverse drug reactions reported for attention deficit hyperactivity disorder (ADHD) medications in the pediatric population: a qualitative review of empirical studies. Neuropsychiatric Disease and Treatment 7, pages 729-744.
Read now
Read now
Keith Saylor, David W. Williams, Kory J. Schuh, Linda Wietecha & Michael Greenbaum. (2010) Effects of atomoxetine on self-reported high-risk behaviors and health-related quality of life in adolescents with ADHD. Current Medical Research and Opinion 26:9, pages 2087-2095.
Read now
Read now
Igor Ondrejka, Osman Abali, Ivo Paclt, Magdolna Gácser, Felicia Iftene, Richard Walton, Gavan Harrison, Tamá Treuer & Ferenc Martényi. (2010) A prospective observational study of attention-deficit/hyperactivity disorder in Central and Eastern Europe and Turkey: Symptom severity and treatment options in a paediatric population. International Journal of Psychiatry in Clinical Practice 14:2, pages 116-126.
Read now
Read now
Michael Manos, Thomas W. Frazier, Jeanne M. Landgraf, Margaret Weiss & Paul Hodgkins. (2009) HRQL and medication satisfaction in children with ADHD treated with the methylphenidate transdermal system. Current Medical Research and Opinion 25:12, pages 3001-3010.
Read now
Read now
Alonso Montoya, Amaia Hervas, Esther Cardo, Josep Artigas, María J. Mardomingo, José A. Alda, Xavier Gastaminza, María J. García-Polavieja, Inmaculada Gilaberte & Rodrigo Escobar. (2009) Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naïve children and adolescents with attention deficit/hyperactivity disorder. Current Medical Research and Opinion 25:11, pages 2745-2754.
Read now
Read now
Katharina Manassis. (2007) When attention-deficit/hyperactivity disorder co-occurs with anxiety disorders: effects on treatment. Expert Review of Neurotherapeutics 7:8, pages 981-988.
Read now
Read now
Articles from other publishers (63)
Armagan ARAL, Merve ONAT & Mirac Baria USTA. (2023) Factors associated with short-term treatment response of atomoxetine in children and adolescents. Minerva Psychiatry 64:2.
Crossref
Crossref
Mats Johnson, Carina Gillberg, Ingrid Vinsa, Gunnar Fransson, Lena Samuelsson, Klara Jakobsson, Sven Östlund, Elisabeth Fernell & Christopher Gillberg. (2021) A randomized controlled trial of a new intervention in early symptomatic syndromes eliciting neurodevelopmental clinical examinations: PR-ESSENCE. European Child & Adolescent Psychiatry 32:1, pages 63-74.
Crossref
Crossref
Michael Huss. 2022. Das Gesundheitswesen und seine volkswirtschaftliche Bedeutung. Das Gesundheitswesen und seine volkswirtschaftliche Bedeutung
161
171
.
蓉 汤. (2021) Research Status of Tic Disorder in Children. Advances in Clinical Medicine 11:03, pages 974-980.
Crossref
Crossref
Zhi-Sheng Liu, Yong-Hua Cui, Dan Sun, Qing Lu, Yu-Wu Jiang, Li Jiang, Jia-Qin Wang, Rong Luo, Fang Fang, Shui-Zhen Zhou, Yi Wang, Fang-Cheng Cai, Qing Lin, Lan Xiong, Yi Zheng & Jiong Qin. (2020) Current Status, Diagnosis, and Treatment Recommendation for Tic Disorders in China. Frontiers in Psychiatry 11.
Crossref
Crossref
David R. Coghill, Alain Joseph, Vanja Sikirica, Mark Kosinski, Caleb Bliss & Michael Huss. (2017) Correlations Between Clinical Trial Outcomes Based on Symptoms, Functional Impairments, and Quality of Life in Children and Adolescents With ADHD. Journal of Attention Disorders 23:13, pages 1578-1591.
Crossref
Crossref
Fahri ÇELEBİ & Dilek ÜNAL. (2019) KLİNİK BİR ÇOCUK-ERGEN ÖRNEKLEMİNDE DEHB İLİŞKİLİ YAŞAM KALİTESİNİN DEĞERLENDİRİLMESİ. Zeynep Kamil Tıp Bülteni 50:2, pages 35-38.
Crossref
Crossref
Jessica L. Gayleard & Matthew P. Mychailyszyn. (2017) Atomoxetine treatment for children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD): a comprehensive meta-analysis of outcomes on parent-rated core symptomatology. ADHD Attention Deficit and Hyperactivity Disorders 9:3, pages 149-160.
Crossref
Crossref
Masako Nakano, Jennifer Witcher, Yoichi Satoi & Taro Goto. (2016) Pharmacokinetic Profile and Palatability of Atomoxetine Oral Solution in Healthy Japanese Male Adults. Clinical Drug Investigation 36:11, pages 903-911.
Crossref
Crossref
Nilüfer Demirsoy & Omur Sayligil. (2016) Validity and reliability of a quality-of-life assessment instrument in children aged between 6 and 11 years. Annals of Saudi Medicine 36:4, pages 269-281.
Crossref
Crossref
Libuše Stárková. (2016) ADHD in the light of contenporary psychiatry and clinical practice. Pediatrie pro praxi 17:1, pages 16-21.
Crossref
Crossref
Anthony Rostain, Peter S. Jensen, Daniel F. Connor, Laura M. Miesle & Stephen V. Faraone. (2013) Toward Quality Care in ADHD. Journal of Attention Disorders 19:2, pages 99-117.
Crossref
Crossref
Nicola C. Savill, Jan K. Buitelaar, Ernie Anand, Kathleen Ann Day, Tamás Treuer, Himanshu P. Upadhyaya & David Coghill. (2015) The Efficacy of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Clinical Research. CNS Drugs 29:2, pages 131-151.
Crossref
Crossref
Ralf W. Dittmann, Tobias Banaschewski, Alexander Schacht & Peter M. Wehmeier. (2014) Findings from the observational COMPLY study in children and adolescents with ADHD: core symptoms, ADHD-related difficulties, and patients’ emotional expression during psychostimulant or nonstimulant ADHD treatment. ADHD Attention Deficit and Hyperactivity Disorders 6:4, pages 291-302.
Crossref
Crossref
S. Hughes, D. Cohen & R. Jaggi. (2014) Differences in reporting serious adverse events in industry sponsored clinical trial registries and journal articles on antidepressant and antipsychotic drugs: a cross-sectional study. BMJ Open 4:7, pages e005535-e005535.
Crossref
Crossref
Jasmin Garg, Priti Arun & B. S. Chavan. (2014) Comparative short term efficacy and tolerability of methylphenidate and atomoxetine in attention deficit hyperactivity disorder. Indian Pediatrics 51:7, pages 550-554.
Crossref
Crossref
Alonso Montoya, Deborah Quail, Ernie Anand, Esther Cardo, José A. Alda & Rodrigo Escobar. (2013) Prognostic factors of improvement in health-related quality of life in atomoxetine-treated children and adolescents with attention-deficit/hyperactivity disorder, based on a pooled analysis. ADHD Attention Deficit and Hyperactivity Disorders 6:1, pages 25-34.
Crossref
Crossref
Joaquin Fuentes, Marina Danckaerts, Esther Cardo, Kanasagabi Puvanendran, Patrick Berquin, Katrien De Bruyckere, Alonso Montoya, Deborah Quail & Rodrigo Escobar. (2013) Long-Term Quality-of-Life and Functioning Comparison of Atomoxetine Versus Other Standard Treatment in Pediatric Attention-Deficit/Hyperactivity Disorder. Journal of Clinical Psychopharmacology 33:6, pages 766-774.
Crossref
Crossref
Tobias Banaschewski, César Soutullo, Michel Lecendreux, Mats Johnson, Alessandro Zuddas, Paul Hodgkins, Ben Adeyi, Liza A. Squires & David Coghill. (2013) Health-Related Quality of Life and Functional Outcomes from a Randomized, Controlled Study of Lisdexamfetamine Dimesylate in Children and Adolescents with Attention Deficit Hyperactivity Disorder. CNS Drugs 27:10, pages 829-840.
Crossref
Crossref
Luigi Mazzone, Valentina Postorino, Laura Reale, Manuela Guarnera, Valeria Mannino, Marco Armando, Laura Fatta, Lavinia De Peppo & Stefano Vicari. (2013) Self-Esteem Evaluation in Children and Adolescents Suffering from ADHD. Clinical Practice & Epidemiology in Mental Health 9:1, pages 96-102.
Crossref
Crossref
N. N. Zavadenko & N. Yu. Suvorinova. (2013) Attention Deficit Hyperactivity Disorder: Selection of the Optimum Duration of Medical Treatment. Neuroscience and Behavioral Physiology 43:3, pages 346-350.
Crossref
Crossref
John T. Mitchell & Scott H. Kollins. 2013. Handbook of Adolescent Health Psychology. Handbook of Adolescent Health Psychology
423
445
.
Gregory W. van Wyk, Philip L. Hazell, Michael R. Kohn, Renee E. Granger & Richard J. Walton. (2011) How Oppositionality, Inattention, and Hyperactivity Affect Response to Atomoxetine Versus Methylphenidate. Journal of Attention Disorders 16:4, pages 314-324.
Crossref
Crossref
Peter M. Wehmeier, Alexander Schacht, Rodrigo Escobar, Amaia Hervas & Ruth Dickson. (2012) Health-related quality of life in ADHD: a pooled analysis of gender differences in five atomoxetine trials. ADHD Attention Deficit and Hyperactivity Disorders 4:1, pages 25-35.
Crossref
Crossref
Michal Goetz, Chin-Bin Yeh, Igor Ondrejka, Aynur Akay, Ilona Herczeg, Iuliana Dobrescu, Boong Nyun Kim, Xingming Jin, Anne W. Riley, Ferenc Martényi, Gavan Harrison & Tamás Treuer. (2010) A 12-Month Prospective, Observational Study of Treatment Regimen and Quality of Life Associated With ADHD in Central and Eastern Europe and Eastern Asia. Journal of Attention Disorders 16:1, pages 44-59.
Crossref
Crossref
Raveen Hanwella, Madhri Senanayake & Varuni de Silva. (2011) Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis. BMC Psychiatry 11:1.
Crossref
Crossref
Alexander Schacht, Rodrigo Escobar, Thomas Wagner & Peter M. Wehmeier. (2011) Psychometric properties of the quality of life scale Child Health and Illness Profile-Child Edition in a combined analysis of five atomoxetine trials. ADHD Attention Deficit and Hyperactivity Disorders 3:4, pages 335-349.
Crossref
Crossref
Philip L. Hazell, Michael R. Kohn, Ruth Dickson, Richard J. Walton, Renee E. Granger & Gregory W. van Wyk. (2010) Core ADHD Symptom Improvement With Atomoxetine Versus Methylphenidate. Journal of Attention Disorders 15:8, pages 674-683.
Crossref
Crossref
David Coghill. (2011) Pragmatic measures in paediatric psychopharmacology — Are we getting it right?. European Neuropsychopharmacology 21:8, pages 571-583.
Crossref
Crossref
David Coghill. (2011) Escalas y cuestionarios pragmáticos en psicofarmacología pediátrica: ¿estamos haciendo lo correcto?. Psiquiatría Biológica 18:3, pages 105-116.
Crossref
Crossref
Peter M. Wehmeier, Alexander Schacht, Ralf W. Dittmann, Karin Helsberg, Christian Schneider-Fresenius, Martin Lehmann, Monika Bullinger & Ulrike Ravens-Sieberer. (2010) Effect of atomoxetine on quality of life and family burden: results from a randomized, placebo-controlled, double-blind study in children and adolescents with ADHD and comorbid oppositional defiant or conduct disorder. Quality of Life Research 20:5, pages 691-702.
Crossref
Crossref
N. N. Zavadenko, N. M. Kolobova & N. Yu. Suvorinova. (2011) Attention Deficit Hyperactivity Disorder and Enuresis in Children and Adolescents. Neuroscience and Behavioral Physiology 41:5, pages 525-531.
Crossref
Crossref
L. S. Chutko, T. I. Anisimova, S. Yu. Surushkina & K. A. Aitbekov. (2011) Family Problems and Family Therapy in Attention Deficit Hyperactivity Disorder. Neuroscience and Behavioral Physiology 41:4, pages 404-407.
Crossref
Crossref
Simon Jones, Emma James & Suyash Prasad. (2011) Disease Registries and Outcomes Research in Children. Pediatric Drugs 13:1, pages 33-47.
Crossref
Crossref
Chris J. BusheNicola Savill. (2011) Atomoxetine in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. Systematic Review of Review Papers 2009-2011. An Update for Clinicians. Journal of Central Nervous System Disease 3, pages JCNSD.S4391.
Crossref
Crossref
N. N. Zavadenko, T. V. Lebedeva, O. V. Schasnaya, A. N. Zavadenko, O. M. Zlobina & N. A. Semenova. (2010) Attention Deficit Hyperactivity Syndrome: The Role of Parent and Teacher Questionnaires in Assessing the Social and Psychological Adaptation of Patients. Neuroscience and Behavioral Physiology 41:1, pages 52-56.
Crossref
Crossref
Peter M Wehmeier, Alexander Schacht, Rodrigo Escobar, Nicola Savill & Val Harpin. (2010) Differences between children and adolescents in treatment response to atomoxetine and the correlation between health-related quality of life and Attention Deficit/Hyperactivity Disorder core symptoms: Meta-analysis of five atomoxetine trials. Child and Adolescent Psychiatry and Mental Health 4:1.
Crossref
Crossref
David Coghill. (2010) The Impact of Medications on Quality of Life in Attention-Deficit Hyperactivity Disorder. CNS Drugs 24:10, pages 843-866.
Crossref
Crossref
Thomas W. FrazierMargaret WeissPaul HodgkinsMichael J. ManosJeanne M. LandgrafChristopher Gibbins. (2010) Time Course and Predictors of Health-Related Quality of Life Improvement and Medication Satisfaction in Children Diagnosed with Attention-Deficit/Hyperactivity Disorder Treated with the Methylphenidate Transdermal System. Journal of Child and Adolescent Psychopharmacology 20:5, pages 355-364.
Crossref
Crossref
Rodrigo Escobar, Alexander Schacht, Peter M. Wehmeier & Thomas Wagner. (2010) Quality of Life and Attention-Deficit/Hyperactivity Disorder Core Symptoms. Journal of Clinical Psychopharmacology 30:2, pages 145-151.
Crossref
Crossref
Peter M. Wehmeier, Alexander Schacht & Russell A. Barkley. (2010) Social and Emotional Impairment in Children and Adolescents with ADHD and the Impact on Quality of Life. Journal of Adolescent Health 46:3, pages 209-217.
Crossref
Crossref
Marina Danckaerts, Edmund J. S. Sonuga-Barke, Tobias Banaschewski, Jan Buitelaar, Manfred Döpfner, Chris Hollis, Paramala Santosh, Aribert Rothenberger, Joseph Sergeant, Hans-Christoph Steinhausen, Eric Taylor, Alessandro Zuddas & David Coghill. (2009) The quality of life of children with attention deficit/hyperactivity disorder: a systematic review. European Child & Adolescent Psychiatry 19:2, pages 83-105.
Crossref
Crossref
Karly P. Garnock-Jones & Gillian M. Keating. (2010) Spotlight on Atomoxetine in Attention-Deficit Hyperactivity Disorder in Children and Adolescents†. CNS Drugs 24:1, pages 85-88.
Crossref
Crossref
Oscar G Bukstein, L Eugene Arnold, Jeanne M Landgraf & Paul Hodgkins. (2009) Does switching from oral extended-release methylphenidate to the methylphenidate transdermal system affect health-related quality-of-life and medication satisfaction for children with attention-deficit/hyperactivity disorder?. Child and Adolescent Psychiatry and Mental Health 3:1.
Crossref
Crossref
Ralf W Dittmann, Peter M Wehmeier, Alexander Schacht, Anette Minarzyk, Martin Lehmann, Kathrin Sevecke & Gerd Lehmkuhl. (2009) Atomoxetine treatment and ADHD-related difficulties as assessed by adolescent patients, their parents and physicians. Child and Adolescent Psychiatry and Mental Health 3:1.
Crossref
Crossref
Michel MaziadeNancie RouleauBobbie LeeAnn RogersLori DavisRuth Dickson. (2009) Atomoxetine and Neuropsychological Function in Children With Attention-Deficit/Hyperactivity Disorder: Results of a Pilot Study. Journal of Child and Adolescent Psychopharmacology 19:6, pages 709-718.
Crossref
Crossref
Ralf W. Dittmann, Peter M. Wehmeier, Alexander Schacht, Martin Lehmann & Gerd Lehmkuhl. (2009) Self-esteem in adolescent patients with attention-deficit/hyperactivity disorder during open-label atomoxetine treatment: psychometric evaluation of the Rosenberg Self-Esteem Scale and clinical findings. ADHD Attention Deficit and Hyperactivity Disorders 1:2, pages 187-200.
Crossref
Crossref
Pär Svanborg, Gunilla Thernlund, Per A. Gustafsson, Bruno Hägglöf, Alexander Schacht & Björn Kadesjö. (2009) Atomoxetine improves patient and family coping in attention deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in Swedish children and adolescents. European Child & Adolescent Psychiatry 18:12, pages 725-735.
Crossref
Crossref
Grazia Dell'Agnello, Dino Maschietto, Carmela Bravaccio, Filippo Calamoneri, Gabriele Masi, Paolo Curatolo, Dante Besana, Francesca Mancini, Andrea Rossi, Lynne Poole, Rodrigo Escobar & Alessandro Zuddas. (2009) Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study. European Neuropsychopharmacology 19:11, pages 822-834.
Crossref
Crossref
Ferenc MartényiTamas TreuerSusan Shur-Fen GauSungdo David HongMária PalaczkyJán ŠubaMircea TiberiuPetra UhlíkováTong XuSalih ZoroğluKenneth D. GadowRichard WaltonGavan Harrison. (2009) Attention-Deficit/Hyperactivity Disorder Diagnosis, Co-Morbidities, Treatment Patterns, and Quality of Life in a Pediatric Population in Central and Eastern Europe and Asia. Journal of Child and Adolescent Psychopharmacology 19:4, pages 363-376.
Crossref
Crossref
S. Prasad, J. Arellano, C. Steer & S. E. Libretto. (2009) Assessing the value of atomoxetine in treating children and adolescents with ADHD in the UK. International Journal of Clinical Practice 63:7, pages 1031-1040.
Crossref
Crossref
Rodrigo EscobarAlonso MontoyaPepa PolaviejaEsther CardoJosep ArtigasAmaia HervasJoaquín Fuentes. (2009) Evaluation of Patients' and Parents' Quality of Life in a Randomized Placebo-Controlled Atomoxetine Study in Attention-Deficit/Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology 19:3, pages 253-263.
Crossref
Crossref
Karly P. Garnock-Jones & Gillian M. Keating. (2009) Atomoxetine. Pediatric Drugs 11:3, pages 203-226.
Crossref
Crossref
Gordon Bates. (2018) Drug treatments for attention-deficit hyperactivity disorder in young people. Advances in Psychiatric Treatment 15:3, pages 162-171.
Crossref
Crossref
David Coghill, Marina Danckaerts, Edmund Sonuga-Barke & Joseph Sergeant. (2009) Practitioner Review: Quality of life in child mental health - conceptual challenges and practical choices. Journal of Child Psychology and Psychiatry 50:5, pages 544-561.
Crossref
Crossref
Peter M Wehmeier, Alexander Schacht, Ralf W Dittmann & Manfred Döpfner. (2008) Global impression of perceived difficulties in children and adolescents with attention-deficit/hyperactivity disorder: Reliability and validity of a new instrument assessing perceived difficulties from a patient, parent and physician perspective over the day. Child and Adolescent Psychiatry and Mental Health 2:1.
Crossref
Crossref
Vittorio Mapelli. (2013) Analisi costo-utilità del trattamento con atomoxetina e metilfenidato nei bambini con disturbi da deficit di attenzione con iperattività (ADHD)Cost-utility analysis of treatment of children with attention deficit hyperactivity disorders (ADHD) with atomoxetine and methylphenidate. PharmacoEconomics Italian Research Articles 10:3, pages 151-160.
Crossref
Crossref
Leo Bastiaens. (2008) Both Atomoxetine and Stimulants Improve Quality of Life in an ADHD Population Treated in a Community Clinic. Psychiatric Quarterly 79:2, pages 133-137.
Crossref
Crossref
Suyash Prasad & Chris Steer. (2008) Switching from Neurostimulant Therapy to Atomoxetine in Children and Adolescents with Attention-Deficit Hyperactivity Disorder. Pediatric Drugs 10:1, pages 39-47.
Crossref
Crossref
Nicola O'Connell. (2007) ADHD medication: useful or useless?. Nurse Prescribing 5:11, pages 478-480.
Crossref
Crossref
Peter M. WehmeierRalf W. DittmannAlexander SchachtAnette MinarzykMartin LehmannKathrin SeveckeGerd Lehmkuhl. (2007) Effectiveness of Atomoxetine and Quality of Life in Children with Attention-Deficit/Hyperactivity Disorder as Perceived by Patients, Parents, and Physicians in an Open-Label Study. Journal of Child and Adolescent Psychopharmacology 17:6, pages 813-830.
Crossref
Crossref
Saroj Jamdar & Brahan Thara Sathyamoorthy. (2007) Management of attention-deficit/ hyperactivity disorder. British Journal of Hospital Medicine 68:7, pages 360-366.
Crossref
Crossref
Nicola O'Connell. (2007) Research and development round-up: March 2007. Nurse Prescribing 5:3, pages 130-133.
Crossref
Crossref